Propagation of human prostate tissue from induced pluripotent stem cells

AC Hepburn, EL Curry, M Moad… - stem cells …, 2020 - academic.oup.com
AC Hepburn, EL Curry, M Moad, RE Steele, OE Franco, L Wilson, P Singh, A Buskin
stem cells translational medicine, 2020academic.oup.com
Primary culture of human prostate organoids and patient-derived xenografts is inefficient
and has limited access to clinical tissues. This hampers their use for translational study to
identify new treatments. To overcome this, we established a complementary approach
where rapidly proliferating and easily handled induced pluripotent stem cells enabled the
generation of human prostate tissue in vivo and in vitro. By using a coculture technique with
inductive urogenital sinus mesenchyme, we comprehensively recapitulated in situ 3D …
Abstract
Primary culture of human prostate organoids and patient-derived xenografts is inefficient and has limited access to clinical tissues. This hampers their use for translational study to identify new treatments. To overcome this, we established a complementary approach where rapidly proliferating and easily handled induced pluripotent stem cells enabled the generation of human prostate tissue in vivo and in vitro. By using a coculture technique with inductive urogenital sinus mesenchyme, we comprehensively recapitulated in situ 3D prostate histology, and overcame limitations in the primary culture of human prostate stem, luminal and neuroendocrine cells, as well as the stromal microenvironment. This model now unlocks new opportunities to undertake translational studies of benign and malignant prostate disease.
Significance statement
Growing cells from prostate cancer biopsies in the laboratory to study mechanisms of disease and to discover new treatments is fraught with difficulties and often not possible. This work establishes a new means to grow “mini 3D prostates” in the laboratory. It shows proof of concept that genetic modifications are possible in this innovative model, which lays the foundations for new preclinical approaches to personalized care previously considered too challenging. Specifically, in future work, one can develop genetically engineered prostate cancers in a dish, tailored to the specific genetic profiles of individual patients, and determine their best response to a range of drug treatments.
Oxford University Press